Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Muhammad Tufail; Jia-Ju Hu; Jie Liang; Cai-Yun He; Wen-Dong Wan; Yu-Qi Huang; Can-Hua Jiang; Hong Wu; Ning Li

doi:10.1186/s12967-023-04841-w

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

J Transl Med. 2024 Jan 3;22(1):15. doi: 10.1186/s12967-023-04841-w.

Authors

Muhammad Tufail¹, Jia-Ju Hu¹, Jie Liang¹, Cai-Yun He¹, Wen-Dong Wan¹, Yu-Qi Huang¹, Can-Hua Jiang^{1

2

3

4}, Hong Wu⁵, Ning Li^{6

7

8

9}

Affiliations

¹ Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China.
² Institute of Oral Precancerous Lesions, Central South University, Changsha, China.
³ Research Center of Oral and Maxillofacial Tumor, Xiangya Hospital, Central South University, Changsha, China.
⁴ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
⁵ State Key Laboratory of Powder Metallurgy, Central South University, Changsha, 410083, China.
⁶ Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China. liningoms@csu.edu.cn.
⁷ Institute of Oral Precancerous Lesions, Central South University, Changsha, China. liningoms@csu.edu.cn.
⁸ Research Center of Oral and Maxillofacial Tumor, Xiangya Hospital, Central South University, Changsha, China. liningoms@csu.edu.cn.
⁹ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. liningoms@csu.edu.cn.

Abstract

Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway has emerged as a crucial contributor to the development, advancement, and resistance to treatment. This review article explores the implications of the PI3K pathway in predictive, preventive, and personalized medicine for BC. It emphasizes the identification of predictive biomarkers, such as PIK3CA mutations, and the utility of molecular profiling in guiding treatment decisions. The review also discusses the potential of targeting the PI3K pathway for preventive strategies and the customization of therapy based on tumor stage, molecular subtypes, and genetic alterations. Overcoming resistance to PI3K inhibitors and exploring combination therapies are addressed as important considerations. While this field holds promise in improving patient outcomes, further research and clinical trials are needed to validate these approaches and translate them into clinical practice.

Keywords: Breast cancer; PI3K pathway; Personalized medicine; Predictive medicine; Preventive medicine.

Publication types

Review

MeSH terms

Breast Neoplasms* / pathology
Class I Phosphatidylinositol 3-Kinases
Female
Humans
Mutation / genetics
Phosphatidylinositol 3-Kinase*
Phosphatidylinositol 3-Kinases / metabolism
Phosphoinositide-3 Kinase Inhibitors / therapeutic use
Precision Medicine
Proto-Oncogene Proteins c-akt / metabolism

Substances

Phosphatidylinositol 3-Kinase
Phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Class I Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins c-akt

Abstract

Publication types

MeSH terms

Substances

Grants and funding